万邦医药
(301520)
| 流通市值：9.46亿 | | | 总市值：28.56亿 |
| 流通股本：2207.34万 | | | 总股本：6666.67万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 293,304,171.94 | 187,214,555.86 | 90,172,342.02 | 341,806,532.85 |
| 营业收入 | 293,304,171.94 | 187,214,555.86 | 90,172,342.02 | 341,806,532.85 |
| 二、营业总成本 | 231,528,566.18 | 141,898,897.72 | 65,349,751.67 | 230,811,694.31 |
| 营业成本 | 166,749,224.26 | 100,891,541.69 | 47,825,532.49 | 174,533,801.52 |
| 税金及附加 | 1,155,391.25 | 755,005.3 | 369,055.88 | 1,160,781.71 |
| 销售费用 | 4,310,502.16 | 2,213,962.16 | 939,770.05 | 4,536,071.16 |
| 管理费用 | 18,945,660.65 | 13,028,848.4 | 6,809,525.67 | 20,674,727.06 |
| 研发费用 | 43,048,445.44 | 27,151,750.82 | 10,738,916.39 | 34,521,095.42 |
| 财务费用 | -2,680,657.58 | -2,142,210.65 | -1,333,048.81 | -4,614,782.56 |
| 其中:利息费用 | 0 | - | 0 | 115.79 |
| 其中:利息收入 | 2,701,972.3 | 2,160,167.37 | 1,338,763.35 | 4,630,628.63 |
| 加:公允价值变动收益 | 20,647,025.67 | 11,983,271.51 | 6,879,458.32 | 3,786,249.98 |
| 加:投资收益 | 2,038,467.95 | 1,329,281.92 | 679,300.01 | 2,433,044.4 |
| 资产处置收益 | 16,439.76 | 16,439.76 | - | - |
| 资产减值损失(新) | -1,708,098.38 | -1,375,071.9 | -448,901.3 | -1,454,080.3 |
| 信用减值损失(新) | -2,410,712.43 | -920,602.46 | -103,996.54 | -2,653,135.76 |
| 其他收益 | 1,107,792.21 | 746,590.24 | 299,034.55 | 5,899,257.48 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 81,466,520.54 | 57,095,567.21 | 32,127,485.39 | 119,006,174.34 |
| 加:营业外收入 | 2,638,315.26 | 2,511,208.86 | 291,700 | 757,586.33 |
| 减:营业外支出 | 49,132.58 | 49,119.12 | 43,418.62 | 118,852.39 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 84,055,703.22 | 59,557,656.95 | 32,375,766.77 | 119,644,908.28 |
| 减:所得税费用 | 6,258,223.49 | 4,524,700.86 | 2,688,682.51 | 11,553,058.97 |
| 六、净利润 | 77,797,479.73 | 55,032,956.09 | 29,687,084.26 | 108,091,849.31 |
| 持续经营净利润 | 77,797,479.73 | 55,032,956.09 | 29,687,084.26 | 108,091,849.31 |
| 归属于母公司股东的净利润 | 77,797,479.73 | 55,032,956.09 | 29,687,084.26 | 108,091,849.31 |
| (一)基本每股收益 | 1.17 | 0.83 | 0.45 | 2 |
| (二)稀释每股收益 | 1.17 | 0.83 | 0.45 | 2 |
| 九、综合收益总额 | 77,797,479.73 | 55,032,956.09 | 29,687,084.26 | 108,091,849.31 |
| 归属于母公司股东的综合收益总额 | 77,797,479.73 | 55,032,956.09 | 29,687,084.26 | 108,091,849.31 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |